Phase II trial of zanzalintinib (XL-092) in combination with durvalumab and tremelimumab in unresectable hepatocellular carcinoma (ZENOBIA).

Authors: Meghana Singh, Naudia L. Jonassaint, John C. Rhee, Vikram C. Gorantla, Ibrahim Halil Sahin, Janie Yue Zhang, Dennis Hsu, Stela Celaj, Scott W. Biggins, Satdarshan Monga, Aatur D. Singhi, David A. Geller, Anwaar Saeed

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.tps4216

Source: Full article

---

Abstract

TPS4216